Videos

February 18, 2025

Botensilimab and Balstilimab – ASCO GI 2025 and Beyond

At the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (GI) in San Francisco, Agenus presented new data on its next-generation immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for colorectal cancer. Join Agenus Chief Medical Officer Dr. Steven O’Day as he explores these findings.